SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
Vigil Neuroscience, Inc. (NASDAQ: VIGL) had its "buy" rating re-affirmed by analysts at Guggenheim.
Vigil Neuroscience, Inc. (NASDAQ: VIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease